The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review

IntroductionThe combination of biomarkers and drugs is the subject of growing interest both from regulators, physicians and companies. This study protocol of a systematic review is aimed to describe available literature evidences about the cost-effectiveness, cost-utility or net-monetary benefit of the use of biomarkers in solid tumour as tools for customising immunotherapy to identify what further research needs.Methods and analysisA systematic review of the literature will be carried out according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines. PubMed and Embase will be queried from June 2010 to June 2021. The PICOS model will be applied: target population (P) will be patients with solid tumours treated with immune checkpoint inhibitors (ICIs); the interventions (I) will be test of the immune checkpoint predictive biomarkers; the comparator (C) will be any other targeted or non-targeted therapy; outcomes (O) evaluated will be health economic and clinical implications assessed in terms of incremental cost-effectiveness ratio, net health benefit, net monetary benefit, life years gained, quality of life, etc; study (S) considered will be economic evaluations reporting cost-effectiveness analysis, cost-utility analysis, net-monetary benefit. The quality of the evidence will be graded according to Grading of Recommendations Assessment, Development and Evaluation.Ethics and disseminationThis systematic review will assess the cost-effectiveness implications of using biomarkers in the immunotherapy with ICIs, which may help to understand whether this approach is widespread in real clinical practice. This research is exempt from ethics approval because the work is carried out on published documents. We will disseminate this protocol in a related peer-reviewed journal.PROSPERO registration numberCRD42020201549.

Download Full-text

3440 The benefits and side effects of denosumab for patients with bone metastases from solid tumours: University hospitals of Leicester experience

European Journal of Cancer ◽

10.1016/s0959-8049(16)31913-x ◽

2015 ◽

Vol 51 ◽

pp. S701-S702

Author(s):

N. Ma ◽

N. Wilson ◽

I. Boiangiu

Keyword(s):

Side Effects ◽

Bone Metastases ◽

Solid Tumours ◽

University Hospitals

Download Full-text

Quality of life of elderly patients with solid tumours undergoing adjuvant cancer therapy: a systematic review

BMJ Open ◽

10.1136/bmjopen-2017-018101 ◽

2018 ◽

Vol 8 (1) ◽

pp. e018101 ◽

Cited By ~ 8

Author(s):

Karis Kin-Fong Cheng ◽

Ethel Yee-Ting Lim ◽

Ravindran Kanesvaran

Keyword(s):

Quality Of Life ◽

Systematic Review ◽

Adjuvant Chemotherapy ◽

Adjuvant Therapy ◽

Elderly Patients ◽

Clinical Decision Making ◽

Clinical Decision ◽

Risk Of Bias ◽

Solid Tumours

ObjectivesThe measurement of quality of life (QoL) in elderly cancer population is increasingly being recognised as an important element of clinical decision-making and the evaluation of treatment outcome. This systematic review aimed to summarise the evidence of QoL during and after adjuvant therapy in elderly patients with cancer.MethodsA systematic search was conducted of studies published in CINAHL plus, CENTRAL, PubMed, PsycINFO and Web of Science from the inception of these databases to December 2016. Eligible studies included RCTs and non-RCTs in which QoL was measured in elderly patients (aged 65 years or above) with stage I–III solid tumours who were undergoing adjuvant chemotherapy and/or radiotherapy. Because of the heterogeneity and the insufficient data among the included studies, the results were synthesised narratively.ResultsWe included 4 RCTs and 14 non-RCTs on 1785 participants. In all four RCTs, the risk of bias was low or unclear for most items but high for detection. Of the 14 non-RCTs, 5 studies were judged to have a low or moderate risk of bias for all domains, and the other 9 studies had a serious risk of bias in at least one domain. The bias was observed mainly in the confounding and in the selection of participants for the study. For most elderly patients with breast cancer, the non-significant negative change in the QoL was transient. A significant increase in the QoL during the course of temozolomide in elderly patients with glioblastoma but a decreasing trend in QoL after radiotherapy was shown. This review also shows a uniform trend of stable or improved QoL during adjuvant therapy and at follow-up evaluations across the studies with prostate, colon or cervical cancer population.ConclusionsThis review suggests that adjuvant chemotherapy and radiotherapy may not have detrimental effects on QoL in most elderly patients with solid tumours.

Download Full-text

The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 1: an overview

BDJ ◽

10.1038/s41415-021-3825-y ◽

2022 ◽

Author(s):

Vinod Patel ◽

Sanford Grossman ◽

Rana Wali ◽

Megan Burns ◽

Sheelen Patel ◽

...

Keyword(s):

Bone Metastases ◽

Dental Status ◽

Solid Tumours ◽

Bone Targeting

Download Full-text

The potential diagnostic value of exosomal long non-coding RNAs in solid tumours: a meta-analysis and systematic review

10.37766/inplasy2020.6.0083 ◽

2020 ◽

Author(s):

Zilong Wu ◽

Zihao Xu ◽

Boyao Yu ◽

Jing tao Zhang ◽

Bentong Yu

Keyword(s):

Systematic Review ◽

Meta Analysis ◽

Diagnostic Value ◽

Solid Tumours ◽

Non Coding Rnas

Download Full-text

Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djz101 ◽

2019 ◽

Vol 111 (10) ◽

pp. 1023-1032 ◽

Cited By ~ 8

Author(s):

Katie L Spencer ◽

Joanne M van der Velden ◽

Erin Wong ◽

Enrica Seravalli ◽

Arjun Sahgal ◽

...

Keyword(s):

Systematic Review ◽

Bone Metastases ◽

Local Control ◽

Stereotactic Radiotherapy ◽

Palliative Radiotherapy ◽

Included Study ◽

Pain Response ◽

Solid Organ ◽

International Consensus ◽

Conventional Radiotherapy

Abstract Background Stereotactic radiotherapy (SBRT) might improve pain and local control in patients with bone metastases compared to conventional radiotherapy, although an overall estimate of these outcomes is currently unknown. Methods A systematic review was carried out following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Pubmed, Embase, and Cochrane databases were systematically searched to identify studies reporting pain response and local control among patients with bone metastases from solid-organ tumors who underwent SBRT in 1–6 fractions. All studies prior to April 15, 2017, were included. Study quality was assessed by predefined criteria, and pain response and local control rates were extracted. Results A total of 2619 studies were screened; 57 were included (reporting outcomes for 3995 patients) of which 38 reported pain response and 45 local control rates. Local control rates were high with pain response rates above those previously reported for conventional radiotherapy. Marked heterogeneity in study populations and delivered treatments were identified such that quantitative synthesis was not appropriate. Reported toxicity was limited. Of the pain response studies, 73.7% used a retrospective cohort design and only 10.5% used the international consensus endpoint definitions of pain response. The median survival within the included studies ranged from 8 to 30.4 months, suggesting a high risk of selection bias in the included observational studies. Conclusions This review demonstrates the potential benefit of SBRT over conventional palliative radiotherapy in improving pain due to bone metastases. Given the methodological limitations of the published literature, however, large randomized trials are now urgently required to better quantify this benefit.

Download Full-text